A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis

Bibliography

• GASS JD: Pathogenesis of disciform detachment of the neuroepithelium. Am. J. Ophthalmol. (1967) 63(Suppl.):S1-S139.
   PubMed Web of Science ®Google Scholar
• HAVENER WH, SHEETS J, COOK MJ: Evaluation of heparin therapy of senile macular degeneration. AMA Arch. Ophthalmol. (1959) 61(3):390-401.
   PubMedGoogle Scholar
• WILLEMSSENS P, HULK J: Research on presbyacusis in patients with senile macular degeneration and treated with vitamin A and E (rovigon) or Roche 1-8307. Pract. Otorhinolaryngol. (Basel) (1960) 22:439-447.
   PubMedGoogle Scholar
• ZWENG HC, LITTLE HL, PEABODY RR: Laser photocoagulation of macular lesions. Tran. Am. Acad. Ophthalmol. Otolaryngol. (1968) 72(3):377-388.
   PubMedGoogle Scholar
• FRANK RN: Argon laser photocoagulation and subretinal neovascularization. Ophthalmic Surg. (1974) 5(2):56-64.
   PubMedGoogle Scholar
• SCHMIDT-ERFURTH U, MILLER J, SICKENBERG M et al.: Photodynamic therapy of subfoveal choroidal neovascularisation: clinical and angiographic examples. Graefes Arch. Clin. Exp. Ophthalmol. (1998) 236(5):365-374.
   PubMed Web of Science ®Google Scholar
• CIULLA TA, DANIS RP, CRISWELL M, PRATT LM: Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. Expert Opin. Investig. Drugs (1999) 8(12):2173-2182.
   PubMedGoogle Scholar
• AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β-carotene, and zinc for age-related macular degeneration and vision loss: AREDS study report no. 8. Arch. Ophthalmol. (2001) 119:1417-1436.
   PubMed Web of Science ®Google Scholar
• VERHOEFF FH, GROSSMAN HP: The pathogenesis of disciform degeneration of the macula. Trans. Am. Ophthalmol. Soc. (1937) 35:262-294.
   PubMedGoogle Scholar
• BIRD AC: Age-related macular disease. Br. J. Ophthalmol. (1996) 80:1-2.
   PubMed Web of Science ®Google Scholar
• IDE AG, BAKER NH, WARREN SL: Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear cham. Roentgenology (1939) 42:891-899.
   Google Scholar
• MICHAELSON IC: The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases. Trans. Ophthalmol. Soc. UK (1948) 68:137-180.
   Google Scholar
• WISE GN: Retinal neovascularization. Trans. Am. Ophthalmol. Soc. (1956) 54:729-826.
   PubMedGoogle Scholar
• ASTON N: Retinal vascularization in health and disease: proctor award lecture of the association for research in ophthalmology. Am. J. Ophthalmol. (1957) 44(4 Part 2):7-17.
   Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285:1182-1186.
   PubMed Web of Science ®Google Scholar
• SENGER DR, GALLI SJ, DVORAK AM et al.: Tumor cells secrete a vascular permeability factor that promotes the accumulation of ascites fluid. Science (1983) 219:983-985.
   PubMed Web of Science ®Google Scholar
• FERRARA N, HENZEL WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. (1989) 161:851-858.
   PubMed Web of Science ®Google Scholar
• FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669-676.
   PubMed Web of Science ®Google Scholar
• LEUNG DW, CACHIANES G, KUANG WJ et al.: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246:1306-1309.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, SHIBUYA M: The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond.) (2005) 109:227-241.
   PubMed Web of Science ®Google Scholar
• YONEKURA H, SAKURAI S, LIU X et al.: Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implications in autocrine and paracrine regulation of angiogenesis. J. Biol. Chem. (1999) 274:35172-35178.
   PubMed Web of Science ®Google Scholar
• OLOFSSON B, KORPELAINEN E, PEPPER MS et al.: Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA (1998) 95:11709-11714.
   PubMed Web of Science ®Google Scholar
• BAUER SM, BAUER RJ, LIU ZJ et al.: Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis and collagen constriction in three-dimensional collagen gels. J. Vasc. Surg. (2005) 41:699-707.
   PubMed Web of Science ®Google Scholar
• STACKER SA, CAESAR C, BALDWIN ME et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. (2001) 7:186-191.
   PubMed Web of Science ®Google Scholar
• KEYT BA, BERLEAU LT, NGUYEN HV et al.: The carboxyl-terminal domain (111 – 165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. (1996) 271:7788-7795.
   PubMed Web of Science ®Google Scholar
• KIM I, RYAN AM, ROHAN R et al.: Constitutive expression of VEGF, VEGF-R1 and VEGF-R2 in normal eyes. Invest. Ophthalmol. Vis. Sci. (1999) 40:2115-2121.
   PubMed Web of Science ®Google Scholar
• KVANTA A, ALGVERE PV, BERGLIN L et al.: Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. (1996) 37:1929-1934.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, AVERY RL, ARRIGG PG et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. (1994) 331:1480-1487.
   PubMed Web of Science ®Google Scholar
• HEFFERNAN JT, FUTTERMAN S, KALINA RE: Dexamethasone inhibition of experimental endothelial cell proliferation in retinal venules. Invest. Ophthalmol. Vis. Sci. (1978) 17(6):565-568.
   PubMed Web of Science ®Google Scholar
• GRAHAM RO, PEYMAN GA: Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch. Ophthalmol. (1974) 92:149-154.
   PubMed Web of Science ®Google Scholar
• MACHEMER R, SUGITA G, TANO Y: Treatment of intraocular proliferations with intravitreal steroids. Trans. Am. Ophthalmol. Soc. (1979) 77:171-180.
   PubMedGoogle Scholar
• SCHINDLER RH, CHANDLER DB, THRESHER R, MACHEMER R: The clearance of intravitreal triamcinolone acetonide. Am. J. Ophthalmol. (1982) 93:415-417.
   PubMed Web of Science ®Google Scholar
• MACHEMER R: Five cases in which a depot steroid, hydrocortisone acetate, and methylprednisolone acetate was injected into the eye. Retina (1996) 16:166-167.
   PubMed Web of Science ®Google Scholar
• JONAS JB: Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol. Scand. (2005) 83:645-663.
   PubMedGoogle Scholar
• PENFOLD PL, GYORY JF, HUNYOR AB, BILLSON FA: Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. NZ J. Ophthalmol. (1995) 23:293-298.
   PubMedGoogle Scholar
• CHALLA JK, GILLIES MC, PENFOLD PL et al.: Exudative macular degeneration and intravitreal triamcinolone: 18-month follow-up. Aust. NZ J. Ophthalmol. (1998) 26:277-281.
   PubMedGoogle Scholar
• JONAS JB, KREISSIG I, DEGENRING RF: Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. (2002) 240:873-874.
   PubMed Web of Science ®Google Scholar
• GILLIES MC, SIMPSON JM, LUO W et al.: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch. Ophthalmol. (2003) 121:667-673.
   PubMed Web of Science ®Google Scholar
• SPAIDE RF, SORENSON J, MARANAN L: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology (2003) 110:1517-1525.
   PubMed Web of Science ®Google Scholar
• ARIAS L, GARCIA-ARUMI J, RAMON JM et al.: Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology (2006) 113(12):2243-2250.
   PubMed Web of Science ®Google Scholar
• CLARK AF: AL-3789: a novel ophthalmic angiostatic steroid. Exp. Opin. Investig. Drugs (1997) 6(12):1867-1877.
   PubMedGoogle Scholar
• CASEY R, LI WW: Factors controlling ocular angiogenesis. Am. J. Ophthalmol. (1997) 124:521-529.
   PubMed Web of Science ®Google Scholar
• The anecortave acetate clinical study group: anecortave avetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD). Retina (2003) 23:14-23.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-ERFURTH U, MICHELS S, MICHELS R, AUE A: Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur. J. Ophthalmol. (2005) 15(4):482-485.
   PubMed Web of Science ®Google Scholar
• SLAKTER JS: Anecortave acetate for treating or preventing choroidal neovascularization. Ophthalmol. Clin. North Am. (2006) 19(3):373-380.
   PubMedGoogle Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• MICHELS S, ROSENFELD PJ, PULIAFITO CA et al.: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology (2005) 112(6):1035-1047.
   PubMed Web of Science ®Google Scholar
• ROSENFELD PJ, MOSHFEGHI AA, PULIAFITO CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthal. Surg. Lasers Imaging (2005) 36(4):331-335.
   PubMed Web of Science ®Google Scholar
• MORDENTI J, CUTHBERTSON RA, FERRARA N et al.: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol. Pathol. (1999) 27(5):536-544.
   PubMed Web of Science ®Google Scholar
• LUTHRA S, NARAYANAN R, MARQUES LE et al.: Evaluation of in vitro effects of bevacizumab (avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina (2006) 26(5):512-518.
   PubMed Web of Science ®Google Scholar
• SHAHAR J, AVERY RL, HEILWEIL G et al.: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin). Retina (2006) 26(3):262-269.
   PubMed Web of Science ®Google Scholar
• AVERY RL, PIERAMICI DJ, RABENA MD et al.: Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology (2006) 113:363-372, E5.
   PubMed Web of Science ®Google Scholar
• SPAIDE RF, LAUD K, FINE HF et al.: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina (2006) 26:383-390.
   PubMed Web of Science ®Google Scholar
• AISENBREY S, ZIEMSSEN F, VOLKER M et al.: Intravitreal bevacizumab (avastin) for occult choroidal neovascularisation in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. (2007) 245(7):941-948.
   PubMed Web of Science ®Google Scholar
• FERRARA N, DAMICO L, SHAMS N et al.: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (2006) 26:859-870.
   PubMed Web of Science ®Google Scholar
• ROSENFELD PJ, BROWN DM, HEIER JS et al.; MARINA study group: Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. (2006) 355:1419-1431.
   PubMed Web of Science ®Google Scholar
• BROWN DM, KAISER PK, MICHELS M et al.; ANCHOR study group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. (2006) 355:1432-1444.
   PubMed Web of Science ®Google Scholar
• FUNG AE, LALWANI GA, ROSENFELD PJ et al.: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. (2007) 143:566-583.
   PubMed Web of Science ®Google Scholar
• HEIER JS, BOYER DS, CIULLA TA et al.: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch. Ophthalmol. (2006) 124(11):1532-1542.
   PubMed Web of Science ®Google Scholar
• GRAGOUDAS ES, ADAMIS AP, CUNNINGHAM ET Jr et al.: Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. (2004) 351(27):2805-2816.
   PubMed Web of Science ®Google Scholar
• GONZALES CR; VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION (VISION) CLINICAL TRIAL GROUP: Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina (2005) 25:815-827.
   PubMed Web of Science ®Google Scholar
• HOLASH J, DAVIS S, PAPADOPOULOS N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA (2002) 99(17):11393-11398.
   PubMed Web of Science ®Google Scholar
• SAISHIN Y, TAKAHASHI K, LIMA E SILVA R et al.: VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell Physiol. (2003) 195(2):241-248.
   PubMed Web of Science ®Google Scholar
• NGUYEN QD, SHAH SM, HAFIZ G et al.: A Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2006) 113(9):1522.E1-1522.E14.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, LENDECKEL W, TUSCHL T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. (2001) 15:188-200.
   PubMed Web of Science ®Google Scholar
• REICH S, FOSNOT J, AKIKO K et al.: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. (2003) 9:210-216.
   PubMed Web of Science ®Google Scholar
• TOLENTINO MJ, BRUCKER AJ, JOSHUA F et al.: Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina (2004) 24:132-138.
   PubMed Web of Science ®Google Scholar
• SHEN J, SAMUL R, SILVA RL et al.: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. (2006) 13(3):225-234.
   PubMed Web of Science ®Google Scholar
• MABJEESH NJ, AMIR S: Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol. Histopathol. (2007) 22(5):559-572.
   PubMed Web of Science ®Google Scholar
• HUNTER T: Signaling: 2000 and beyond. Cell (2000) 100:113-127.
   PubMed Web of Science ®Google Scholar
• ROBINSON DR, WU YM, LIN SF: The protein tyrosine kinase family of the human genome. Oncogene (2000) 19:5548-5557.
   PubMed Web of Science ®Google Scholar
• BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 411:355-365.
   PubMed Web of Science ®Google Scholar
• MAIER P, UNSOELD AS, JUNKER B et al.: Intravitreal injection of specific receptor kinase inhibitor PTK787/ZK222584 improves ischemia-induced retinopathy in mice. Graefes Arch. Clin. Exp. Ophthalmol. (2005) 243(6):593-600.
   PubMed Web of Science ®Google Scholar
• HANKS SK, QUINN AM: Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol. (1991) 200:38-62.
   PubMed Web of Science ®Google Scholar
• ADAMS RH, WILKINSON GA, WEISS C et al.: Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. (1999) 3:295-306.
   Google Scholar
• DAWSON DW, VOLPERT OV, GILLIS P et al.: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. (1999) 237:97-132.
   PubMed Web of Science ®Google Scholar
• STELLMACH V, CRAWFORD SE, ZHOU W, BOUCK N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. USA (2001) 98:2593-2597.
   PubMed Web of Science ®Google Scholar
• MORI K, GEHLBACH P, YAMAMOTO S et al.: AAV-mediated gene transfer of pigment epithelium-derived growth factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2002) 43:1994-2000.
   PubMed Web of Science ®Google Scholar
• RENNO RZ, YOUSSRI AI, MICHAUD N et al.: Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2002) 43:1574-1580.
   PubMed Web of Science ®Google Scholar
• HOLEKAMP NM, BOUCK N, VOLPERT O: Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. (2002) 134:220-227.
   PubMed Web of Science ®Google Scholar
• EBLE JA: The molecular basis of integrin–extracellular matrix interactions. Osteoarthritis Cartilage (2001) 9:S131-S140.
   Google Scholar
• EMSLEY J, KNIGHT CG, FARNDALE RW, BARNES MJ, LIDDINGTON RC: Structural basis of collagen recognition by integrin α2β1. Cell (2000) 100:47-56.
   Google Scholar
• ARNAOUT MA, GOODMAN SL, XIONG JP: Coming to grips with integrin binding to ligands. Curr. Opin Cell Biol. (2002) 14:641-651.
   PubMed Web of Science ®Google Scholar
• SURI C, JONES PF, PATAN S et al.: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 87:1171-1180.
   PubMed Web of Science ®Google Scholar
• THURSTON G, RUDGE JS, IOFFE E et al.: Angiopoietin-1 protects adult vasculature against plasma leakage. Nat. Med. (2000) 6:460-463.
   PubMed Web of Science ®Google Scholar
• OH H, TAKAGI H, SUZUMA K et al.: Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. (1999) 274:15732-15739.
   PubMed Web of Science ®Google Scholar
• HANGAI M, MURATA T, MIYAWAKI N et al.: Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest. Opthalmol. Vis. Sci. (2001) 42:1617-1625.
   PubMed Web of Science ®Google Scholar
• JOUSSEN AM, POULAKI V, TSUJIKAWA A et al.: Suppression of diabetic retinopathy with angiopoietin-1. Am. J. Pathol. (2002) 160:1683-1693.
   PubMed Web of Science ®Google Scholar
• CUILLA TA, CRISWELL MH, DANIS RP et al.: Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina (2003) 23(6):808-814.
   PubMed Web of Science ®Google Scholar
• AUGUSTIN AJ, PULS S, OFFERMANN I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina (2007) 27(2):133-140.
   PubMed Web of Science ®Google Scholar